These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 2395859)

  • 1. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates.
    Daar ES; Li XL; Moudgil T; Ho DD
    Proc Natl Acad Sci U S A; 1990 Sep; 87(17):6574-8. PubMed ID: 2395859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative resistance of primary HIV-1 isolates to neutralization by soluble CD4.
    Daar ES; Ho DD
    Am J Med; 1991 Apr; 90(4A):22S-26S. PubMed ID: 2018048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Envelope proteins from clinical isolates of human immunodeficiency virus type 1 that are refractory to neutralization by soluble CD4 possess high affinity for the CD4 receptor.
    Brighty DW; Rosenberg M; Chen IS; Ivey-Hoyle M
    Proc Natl Acad Sci U S A; 1991 Sep; 88(17):7802-5. PubMed ID: 1909031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4.
    Orloff SL; Kennedy MS; Belperron AA; Maddon PJ; McDougal JS
    J Virol; 1993 Mar; 67(3):1461-71. PubMed ID: 8437224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4.
    Moore JP; McKeating JA; Norton WA; Sattentau QJ
    J Virol; 1991 Mar; 65(3):1133-40. PubMed ID: 1995942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase 1 study.
    Kahn JO; Allan JD; Hodges TL; Kaplan LD; Arri CJ; Fitch HF; Izu AE; Mordenti J; Sherwin JE; Groopman JE
    Ann Intern Med; 1990 Feb; 112(4):254-61. PubMed ID: 2297204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of envelope V3 loop as the major determinant of CD4 neutralization sensitivity of HIV-1.
    Hwang SS; Boyle TJ; Lyerly HK; Cullen BR
    Science; 1992 Jul; 257(5069):535-7. PubMed ID: 1636088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Equal levels of gp120 retention and neutralization resistance of phenotypically distinct primary human immunodeficiency virus type 1 variants upon soluble CD4 treatment.
    Groenink M; Moore JP; Broersen S; Schuitemaker H
    J Virol; 1995 Jan; 69(1):523-7. PubMed ID: 7983749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective ex vivo neutralization of human immunodeficiency virus type 1 in plasma by recombinant immunoglobulin molecules.
    Gauduin MC; Allaway GP; Maddon PJ; Barbas CF; Burton DR; Koup RA
    J Virol; 1996 Apr; 70(4):2586-92. PubMed ID: 8642690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary HIV-1 isolates refractory to neutralization by soluble CD4 are potently inhibited by CD4-Pseudomonas exotoxin.
    Kennedy PE; Moss B; Berger EA
    Virology; 1993 Jan; 192(1):375-9. PubMed ID: 8517027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macrophage-tropic and T-cell line-adapted chimeric strains of human immunodeficiency virus type 1 differ in their susceptibilities to neutralization by soluble CD4 at different temperatures.
    O'Brien WA; Mao SH; Cao Y; Moore JP
    J Virol; 1994 Aug; 68(8):5264-9. PubMed ID: 8035523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial.
    Schooley RT; Merigan TC; Gaut P; Hirsch MS; Holodniy M; Flynn T; Liu S; Byington RE; Henochowicz S; Gubish E
    Ann Intern Med; 1990 Feb; 112(4):247-53. PubMed ID: 2297203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naturally occurring soluble CD4 in patients with human immunodeficiency virus infection.
    Peakman M; Senaldi G; Foote N; McManus TJ; Vergani D
    J Infect Dis; 1992 May; 165(5):799-804. PubMed ID: 1349032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of continuous-infusion soluble CD4 as a single agent and in combination with oral dideoxyinosine therapy in children with symptomatic human immunodeficiency virus infection.
    Husson RN; Chung Y; Mordenti J; Butler KM; Chen S; Duliege AM; Brouwers P; Jarosinski P; Mueller BU; Ammann A
    J Pediatr; 1992 Oct; 121(4):627-33. PubMed ID: 1357124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance of primary isolates of human immunodeficiency virus type 1 to soluble CD4 is independent of CD4-rgp120 binding affinity.
    Ashkenazi A; Smith DH; Marsters SA; Riddle L; Gregory TJ; Ho DD; Capon DJ
    Proc Natl Acad Sci U S A; 1991 Aug; 88(16):7056-60. PubMed ID: 1871120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased sensitivity to CD4 binding site-directed neutralization following in vitro propagation on primary lymphocytes of a neutralization-resistant human immunodeficiency virus IIIB strain isolated from an accidentally infected laboratory worker.
    Beaumont T; Quakkelaar E; van Nuenen A; Pantophlet R; Schuitemaker H
    J Virol; 2004 Jun; 78(11):5651-7. PubMed ID: 15140962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble CD4 enhances simian immunodeficiency virus SIVagm infection.
    Werner A; Winskowsky G; Kurth R
    J Virol; 1990 Dec; 64(12):6252-6. PubMed ID: 1700834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blocking of human immunodeficiency virus infection depends on cell density and viral stock age.
    Layne SP; Merges MJ; Spouge JL; Dembo M; Nara PL
    J Virol; 1991 Jun; 65(6):3293-300. PubMed ID: 1674549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping genetic determinants for human immunodeficiency virus type 1 resistance to soluble CD4.
    O'Brien WA; Chen IS; Ho DD; Daar ES
    J Virol; 1992 May; 66(5):3125-30. PubMed ID: 1373203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates.
    Kessler JA; McKenna PM; Emini EA; Chan CP; Patel MD; Gupta SK; Mark GE; Barbas CF; Burton DR; Conley AJ
    AIDS Res Hum Retroviruses; 1997 May; 13(7):575-82. PubMed ID: 9135875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.